Cadmium Linked With Increased Endometrial Cancer Rates

Article

Women with increased levels of cadmium, which mimics estrogen in the body, had a higher risk of endometrial cancer, according to a recently published observational study.

Jane McElroy, PhD

Women with increased levels of cadmium, which mimics estrogen in the body, had a higher risk of endometrial cancer, according to a 5-year observational study published in PLOS One. Smoking increases cadmium levels, and the metal is found in certain foods such as shellfish.

“Endometrial cancer has been associated with estrogen exposure,” said lead author Jane A. McElroy, PhD, of the Missouri University School of Medicine, in a press release. “Because cadmium mimics estrogen, it may lead to an increased growth of the endometrium, contributing to an increased risk of endometrial cancer.”

The researchers identified 631 incident cases of endometrial cancer-from cancer registries in Arkansas, Iowa, and Missouri-diagnosed from 2010 to 2012. Among these, 86% had type I endometrial cancer, which are mostly endometrioid adenocarcinomas driven by hormonal mechanisms; and 14% had type II endometrial cancer, which are mostly clear cell or serous histology. For controls they included 879 healthy, age-matched women randomly selected from voter registration rolls in Missouri and Iowa (mean age, 65 years).

Participants completed a survey with over 200 questions on potential endometrial cancer risk factors. After the survey, they were sent kits for saliva and urine collection, which were analyzed for cadmium levels-498 patients with endometrial cancer (79%) and 545 controls (61%) returned urine specimens.

“When comparing the cadmium levels of the individuals with endometrial cancer to the control group, we found a statistically significant increased risk of the cancer associated with a woman’s cadmium levels,” McElroy said. “We found the rate of endometrial cancer incidence increased by 22% in individuals with increased cadmium levels.”

After multivariable adjustments, the researchers found that a doubling of cadmium exposure was associated with a significant increased endometrial cancer risk (odds ratio [OR], 1.22; 95% CI, 1.03–1.44).

“We all have cadmium present in our kidneys and livers, but smoking has been shown to more than double a person’s cadmium exposure,” McElroy said.

When the researchers excluded current smokers, the results remained significant (OR, 1.19; 95% CI, 1.01–1.41).

“To our knowledge, this is the first published report on cadmium exposure and endometrial cancer risk using urine as a biomarker for cadmium measurement,” they wrote. “Inconsistent observational studies using estimated cadmium exposure from self-reported dietary intake has brought the validity of food frequency questionnaires for cadmium estimation into question.”

The authors highlighted several limitations of their study, including low participation among women diagnosed with endometrial cancer (631 of 2,597 incident cases), as well as some case information that was self-reported and the possibility of selection and recall bias.

The researchers suggest that further studies use urinary cadmium as a biomarker.

Recent Videos
A prospective trial may help affirm ctDNA as a non-invasive option of predicting responses to radiotherapy among those with gynecologic cancers.
ctDNA reductions or clearance also appeared to correlate with a decrease in disease burden during the pre-boost phase of radiotherapy.
Investigators evaluated ctDNA as a potentially noninvasive method to predict response to radiotherapy among those with gynecologic malignancies.
The Foundation for Women’s Cancer provides multicultural resources for patients with gynecologic cancers to help address gaps in care.
Ginger J. Gardner, MD, FACOG, addresses the growing uterine cancer cases among patients in the United States and the need for greater genetic testing.
Ginger J. Gardner, MD, FACOG, discussed the state of gynecologic cancers and her role in empowering research, education, and awareness surrounding them.
Ritu Salani, MD, discussed investigational endometrial cancer treatment options for patients with varying subtypes of endometrial cancer.
The second interim analysis of the phase 3 RUBY trial found the safety profile was consistent with the first interim analysis and no new deaths due to AEs were observed.
Related Content